AstraZeneca PLC (AZN)
| Market Cap | 290.91B +33.6% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 28.00 |
| Forward PE | 17.63 |
| Dividend | $3.20 (1.71%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 1,803,282 |
| Open | 186.69 |
| Previous Close | 184.64 |
| Day's Range | 185.73 - 188.31 |
| 52-Week Range | 134.90 - 212.71 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 224.49 (+19.75%) |
| Earnings Date | Apr 29, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $224.49, which is an increase of 19.75% from the latest price.
News
AstraZeneca designates key managerial personnel for materiality determination
AstraZeneca Pharma India has notified the National Stock Exchange of India and BSE Limited of the contact details of Key Managerial Personnel authorised to determine the materiality of events and…
Top 5 FTSE 100 AI Stocks to Watch in 2026: Exposure Across Pharma, Defense and Infrastructure
In 2026, several FTSE 100 companies, including AstraZeneca and Rolls-Royce, are leveraging AI for growth, despite the index's limited direct AI representation. These firms illustrate AI's indirect imp...
AstraZeneca (AZN) Faces Potential Market Shifts Amid Trump's Prescription Plan
AstraZeneca (AZN) Faces Potential Market Shifts Amid Trump's Prescription Plan
AstraZeneca (AZN) Secures FDA Approval for Groundbreaking Treatment
AstraZeneca (AZN) Secures FDA Approval for Groundbreaking Treatment
US Supreme Court rebuffs pharma challenge to Biden-era drug price
The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that...
Jefferies says Baxfendy approval may be incrementally constructive for Mineralys
Jefferies analyst Dennis Ding notes that AstraZeneca’s (AZN) Baxfendy was approved by the FDA as the first-ever aldosterone synthase inhibitor, adding that Baxfendy’s approval may be “incrementally co...
The Zacks Analyst Blog Highlights Costco, Coca-Cola, AstraZeneca and Franklin Financial Services
Costco, Coca-Cola, AstraZeneca and Franklin Financial Services are highlighted for resilient growth and strong execution.
AstraZeneca (AZN) Receives US Approval for Innovative Hypertension Treatment
AstraZeneca (AZN) Receives US Approval for Innovative Hypertension Treatment
AstraZeneca (AZN) Secures FDA Approval for Novel Hypertension Treatment
AstraZeneca (AZN) Secures FDA Approval for Novel Hypertension Treatment
AstraZeneca Announces FDA Approval Of BAXFENDY For Hypertension
LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said BAXFENDY has been approved in the US as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combin...
AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA Approval In Two Early Breast Cancer Indications
(RTTNews) - AstraZeneca(AZN, AZN.L, ZEG.DE, AZN.ST) and Daiichi Sankyo Company's (4568.T) ENHERTU has been approved by the US Food and Drug Administration (FDA) for both neoadjuvant or use before surg...
AstraZeneca announces U.S. approval for BAXFENDY in hypertension
AstraZeneca’s (AZN) BAXFENDY has been approved in the US as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive medications, to...
AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug
AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combin...
AstraZeneca’s Baxfendy approved in U.S. for treatment of hypertension
AstraZeneca’s (AZN) Baxfendy has been approved in the US as a first-in-class aldosterone synthase inhibitor, ASI, for the treatment of hypertension in combination with other antihypertensive medicatio...
AstraZeneca (AZN) Gains Approval for New Hypertension Drug Baxfendy
AstraZeneca (AZN) Gains Approval for New Hypertension Drug Baxfendy
‘We Have Been Waiting… for Many Years’: AstraZeneca Stock (AZN) Drops despite Win for Potential Blockbuster Pill
AstraZeneca’s ($AZN) shares edged lower early Monday despite the British pharma giant securing approval for its Baxfendy (baxdrostat) blood pressure pill. The drug is seen as a blockbuster drug candid...
AstraZeneca (AZN) Receives FDA Approval for Baxfendy in Hypertension Treatment
AstraZeneca (AZN) Receives FDA Approval for Baxfendy in Hypertension Treatment
AstraZeneca Gets U.S. Approval for Hypertension Drug
The pharmaceutical company expects the drug Baxfendy to generate multibillion-dollar annual sales at its peak.
AstraZeneca's blood pressure drug wins U.S. approval
Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill baxdrostat had been approved in the United States, offering a new treatment option for millions of patients with uncontrolled h...
AstraZeneca (AZN) Receives FDA Approval for Enhertu in Breast Cancer Treatment
AstraZeneca (AZN) Receives FDA Approval for Enhertu in Breast Cancer Treatment
AstraZeneca :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings
LONDON (dpa-AFX) - The US Food and Drug Administration approved AstraZeneca (AZN) and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of ...
AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings
(RTTNews) - The US Food and Drug Administration approved AstraZeneca (AZN) and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients wi...
Daiichi Sankyo, AstraZeneca’s Enhertu approved by U.S. FDA
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) Enhertu has been approved by the US Food and Drug Administration, FDA, for both the neoadjuvant and adjuvant treatment of patients with HER2-positive ear...
AstraZeneca (AZN) Gains FDA Approval for Enhertu in Breast Cancer Treatments
AstraZeneca (AZN) Gains FDA Approval for Enhertu in Breast Cancer Treatments